Drug Trial Radar · NCT04575597
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,735
Actual
Start
Oct 19, 2020
Primary completion
May 5, 2022
Study completion May 5, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29
Conditions
- Coronavirus Disease (COVID-19)
Interventions
MolnupiravirDrug
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
PlaceboDrug
Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Were Hospitalized and/or Died Through Day 29 (Primary Pre-specified Analysis)Time frame: Up to 29 days
- Number of Participants With an Adverse Event (AE)Time frame: Up to 318 days
- Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to 5 days
Locations
173 sites in 23 countries. Site status is shown where the registry gives one.
Phoenix Medical Group ( Site 1822)
Peoria, Arizona
Ruane Clinical Research Group, Inc. ( Site 2406)
Los Angeles, California
Men's Health Foundation ( Site 1820)
Los Angeles, California
Carbon Health Technologies Inc ( Site 2505)
North Hollywood, California
UC Davis Medical Center ( Site 1833)
Sacramento, California
Emerson Clinical Research Institute ( Site 1828)
Washington D.C., District of Columbia
JEM Research Institute ( Site 2508)
Atlantis, Florida
Midway Immunology and Research Center ( Site 1837)
Ft. Pierce, Florida
Indago Research & Health Center, Inc ( Site 1809)
Hialeah, Florida
Advanced Research For Health Improvement LLC ( Site 1816)
Immokalee, Florida
Advanced Medical Research, LLC ( Site 1864)
Miami, Florida
Advanced Research For Health Improvement LLC ( Site 1813)
Naples, Florida
Bliss Healthcare Services ( Site 1847)
Orlando, Florida
Javara Inc. ( Site 1869)
Albany, Georgia
IACT Health ( Site 1818)
Columbus, Georgia
Javara Inc. ( Site 1868)
Fayetteville, Georgia
Loretto Hospital ( Site 1886)
Chicago, Illinois
Jadestone Clinical Research, LLC ( Site 2502)
Laurel, Maryland
Michigan Center of Medical Research ( Site 2500)
Farmington Hills, Michigan
University of Nebraska Medical Center ( Site 2414)
Omaha, Nebraska
Amici Clinical Research LLC ( Site 2507)
Raritan, New Jersey
University of New Mexico, Health Sciences Center ( Site 1819)
Albuquerque, New Mexico
AXCES Research Group ( Site 2418)
Santa Fe, New Mexico
Saint Hope Foundation, Inc. ( Site 1830)
Bellaire, Texas
The Crofoot Research Center, Inc. ( Site 1812)
Houston, Texas
Javara Inc. ( Site 1866)
Sugar Land, Texas
Clinical Research Partners, LLC. ( Site 2503)
Richmond, Virginia
Swedish Medical Center First Hill ( Site 1807)
Seattle, Washington
Fred Hutchinson Cancer Center ( Site 1829)
Seattle, Washington
Multicare Health System ( Site 1811)
Spokane, Washington
Multicare Health System ( Site 1814)
University Place, Washington
Medical College Of Wisconsin ( Site 2510)
Milwaukee, Wisconsin
Clinica Independencia ( Site 3400)
Vicente López, Buenos Aires, Argentina
Instituto Medico de la Fundacion Estudios Clinicos ( Site 3401)
Rosario, Santa Fe Province, Argentina
Instituto de Infectologia Emilio Ribas ( Site 0153)
São Paulo, Brazil
Centro de Pesquisa Clinica II - ICHC - FMUSP ( Site 0152)
São Paulo, Brazil
Chronos Pesquisa Clínica ( Site 0155)
Brasília, Federal District, Brazil
Santa Casa de Misericordia de Belo Horizonte ( Site 0150)
Belo Horizonte, Minas Gerais, Brazil
Hospital de Clinicas da Universidade Federal do Parana ( Site 0154)
Curitiba, Paraná, Brazil
Hospital Tacchini ( Site 0157)
Bento Gonçalves, Rio Grande do Sul, Brazil
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.